

## **BONESUPPORT™ and Lund University to present at Orthopaedic Research Society (ORS) 2019 Annual Meeting**

**Lund, Sweden, 08.00 CET, 1 February 2019 – BONESUPPORT™**, an emerging leader in orthobiologics for the management of bone voids, today announces two oral presentations, and three poster presentations at the upcoming Orthopaedic Research Society (ORS) 2019 Annual Meeting. The meeting takes place from February 2-5 at the Austin Convention Center in Austin, Texas and is the leading global forum for the presentation of high-quality, innovative orthopaedic research.

The research to be presented was carried out by Lund University in Sweden and BONESUPPORT™. Professor Lars Lidgren at Lund University commented: “We are pleased to complement data to be presented by BONESUPPORT on the elution of the antibiotics Gentamicin and Vancomycin from the bone graft substitute CERAMENT® with important new findings. Our studies, performed in international collaboration, highlight the benefits of using an effective carrier platform. We find that controlled sustained local delivery of active drugs enhance bone repair and improve implant anchorage”.

BONESUPPORT CMO Dr. Michael Diefenbeck said: “The research on the CERAMENT platform by Lund University and their international co-workers reaffirms our confidence in the potential of our preclinical pipeline, focused on exploiting the drug eluting properties of CERAMENT based carriers, in meeting global unmet needs in both fracture repair and prevention. The potential of CERAMENT to elute different bone active drugs are clearly shown by the work from Lund University”

### **The details of the presentations are as follows:**

#### Oral presentation:

Deepak Bushan Raina<sup>1</sup>, Irfan Qayoom<sup>2</sup>, David Larsson<sup>1,3</sup> Ming Hao Zheng<sup>4</sup>, Ashok Kumar<sup>2</sup>, Hanna Isaksson<sup>1,5</sup>, Lars Lidgren<sup>1</sup>, Magnus Tägil<sup>1</sup>

#### Guided Tissue Engineering of the Cortical and Cancellous Bone

<sup>1</sup>Orthopedics, Lund University, Sweden

<sup>2</sup>Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, UP, India

<sup>3</sup>Medical Faculty, Umeå University, Sweden

<sup>4</sup>Health and Medical Sciences, University of Western Australia, Australia

<sup>5</sup>Biomedical Engineering, Lund University, Sweden

## Press Release

### e-Poster with oral presentation

Deepak Bushan Raina<sup>1</sup>, David Larsson<sup>1,2</sup>, Erdem Aras Sezgin<sup>1</sup>, Hanna Isaksson<sup>1,3</sup>, Magnus Tägil<sup>1</sup>, Lars Lidgren<sup>1</sup>

### Biomodulated Implant Increases Bone Formation and Integration

<sup>1</sup>Orthopedics, Lund University, Sweden

<sup>2</sup>Medical Faculty, Umeå University, Sweden

<sup>3</sup>Biomedical Engineering, Lund University, Sweden

### Poster presentation:

Irfan Qayoom<sup>1</sup>, Deepak Bushan Raina<sup>2</sup>, Prem Anand Murugan<sup>1</sup>, Magnus Tägil<sup>2</sup>, Matheshwaran Saravanan<sup>1</sup>, Lars Lidgren<sup>2</sup>, Ashok Kumar<sup>1</sup>

### Local drug delivery in bone tuberculosis using an injectable biphasic calcium sulphate hydroxyapatite bone cement as a carrier

<sup>1</sup>Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, UP, India

<sup>2</sup>Department of Orthopedics, Medical Faculty, Clinical Sciences Lund, Lund University.

Christina Perdikouri, Eva Lidén, Michael Diefenbeck

### Local Antibiotic Use: An in vitro and in vivo investigation of an injectable Calcium Sulfate/Calcium Phosphate Bone Graft Substitute loaded with Gentamicin or Vancomycin

BONESUPPORT AB, Lund, Sweden

Joeri Kok<sup>1</sup>, Aurimas Širka<sup>2</sup>, Lorenzo Grassi<sup>1</sup>, Deepak Bushan Raina<sup>1</sup>, Šarūnas Tarasevičius<sup>2</sup>, Magnus Tägil<sup>1</sup>, Lars Lidgren<sup>1</sup>, Hanna Isaksson<sup>1</sup>

### Fracture strength of the proximal femur injected with a Calcium Sulfate/Hydroxyapatite bone substitute

<sup>1</sup>Lund University, Lund, Sweden

<sup>2</sup>Lithuanian University of Health Sciences, Kaunas, Lithuania

## **About BONESUPPORT™**

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 129 million in 2017. Please visit [www.bonesupport.com](http://www.bonesupport.com) for more information.

BONESUPPORT and CERAMENT are registered trademarks.

## Press Release

**For more information contact:**

**BONESUPPORT AB**

Emil Billbäck, CEO  
+46 (0) 46 286 53 70

Håkan Johansson, CFO  
+46(0) 46 286 53 70  
[ir@bonesupport.com](mailto:ir@bonesupport.com)

**Cord Communications**

Charlotte Stjerngren  
+46 (0)708 76 87 87  
[charlotte.stjerngren@cordcom.se](mailto:charlotte.stjerngren@cordcom.se)  
[www.cordcom.se](http://www.cordcom.se)

*This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 1 February 2019.*